...
【24h】

Prognostic value of proliferating cell nuclear antigen in parotid gland cancer.

机译:增殖细胞核抗原在腮腺癌中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

Although cell proliferation is related to tumour aggressiveness and prognosis, there are few studies describing the expression of proliferative markers in salivary gland cancer. Our aim was to assess the long-term prognostic value of the proliferating cell nuclear antigen (PCNA) in a large group of histologically different salivary gland cancers. We analysed the expression of PCNA in 159 patients with parotid gland cancer by means of immunohistochemistry. The mean follow-up time was 56.6 months. A high expression of PCNA showed a significant correlation to the patients' pathological lymph node stage (p = 0.004). A high PCNA expression significantly indicated a poor 5-year disease-free (p = 0.046) and overall survival rate (p = 0.018). The PCNA expression was the only prognostic factor for a worse 5-year disease-free and overall survival in acinic cell carcinomas (p = 0.004, p = 0.022). The correlation between PCNA expression and survival probabilities of salivary gland cancer might make proliferation markers helpful tools in patient follow-up, prognosis and targeted therapy in salivary gland cancer in future.
机译:尽管细胞增殖与肿瘤的侵袭性和预后有关,但很少有研究描述唾液腺癌中增殖标志物的表达。我们的目的是评估大量组织学上不同的涎腺癌中增殖细胞核抗原(PCNA)的长期预后价值。我们通过免疫组织化学分析了159例腮腺癌中PCNA的表达。平均随访时间为56.6个月。 PCNA的高表达与患者的病理淋巴结分期显着相关(p = 0.004)。高PCNA表达显着表明不良5年无病(p = 0.046)和总生存率(p = 0.018)。 PCNA表达是腺癌细胞5年无病生存期和总体生存期恶化的唯一预后因素(p = 0.004,p = 0.022)。 PCNA表达与唾液腺癌生存率之间的相关性可能使增殖标志物成为未来唾液腺癌患者随访,预后和靶向治疗的有用工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号